Press Release

<< Back
Printer Friendly Version View printer-friendly version
BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 26, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that management will present a corporate overview at the NobleCon13 - Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Monday, January 30, at 11:00 a.m. Eastern Standard Time.

A high-definition video webcast of BioTime’s presentation and a copy of the presentation will be available at noblemediasite.com and on the Company's web site at www.biotimeinc.com. Microsoft’s SilverLight viewer will be needed to participate. The webcast and presentation will be archived on BioTime’s website at www.biotimeinc.com following the event.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells. Pluripotent cells are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

Source: BioTime, Inc.

Investor Contact:
EVC Group, Inc.
Matt Haines, 917-733-9297
mhaines@evcgroup.com
or
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com